FAQs about ATA188 in MS

ATA188 is an investigational therapy, still in testing, that has not been approved to treat multiple sclerosis (MS) or any other condition. It is made of immune T-cells from healthy donors that can specifically eliminate cells infected with the Epstein-Barr virus (EBV), a leading cause of MS. By killing EBV-infected cells, ATA188 is expected to slow or even halt MS progression.

ATA188 has shown encouraging results in a Phase 1 trial involving people with nonactive, progressive forms of multiple sclerosis (MS). Data from the Phase 2 portion of that trial is expected in late 2023, but further Phase 3 studies will be needed to confirm the therapy’s safety and efficacy. Two Phase 3 trials are planned for ATA188 in the future, but it is still too early to know if or when the therapy might be approved by the U.S. Food and Drug Administration.

Clinical trials of ATA188 have excluded patients who were pregnant or breastfeeding, so it is not known if the treatment can be safely used during pregnancy.

Multiple sclerosis can manifest differently in each patient, so individual responses to treatment may vary. In a Phase 1 clinical trial, disability improvements were evident in some patients at as early as three months after starting ATA188 treatment.

Neither hair loss nor weight gain have been reported as ATA188 side effects in multiple sclerosis clinical trials. Patients who experience these or other unexpected reactions to any medication should speak with their healthcare team.

Related Articles